Histological and immunohistochemical findings of the action of botulinum toxin in salivary gland: systematic review

Oliveira, Jaciel Benedito de; Evêncio-Neto, Joaquim; Baratella-Evêncio, Liriane

doi:10.1590/1519-6984.11115

Cited by 12 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vivo studies were conducted to evaluate the effects of BoNT on salivary glands (parotid and submandibular) and to determine its mechanisms of action. A recent review (Oliveira et al 2016) found similar immunohistochemical results among different preclinical experiments. Injection of BoNT-A into salivary glands of animals caused reduced immunoreactivity of immunohistochemical markers (acetylcholinesterase, nitric oxide synthase, SNAP25) in toxintreated groups of most investigations.…”

Section: Preclinical Researchmentioning

confidence: 75%

Botulinum Toxin Type A in Dental Medicine

et al. 2019

View full text Add to dashboard Cite

Botulinum toxins (BoNTs) are a product of the bacteria Clostridium botulinum. By entering nerve endings, they cleave and inactivate SNARE proteins, which are essential for neurotransmitter release. Prevention of acetylcholine release at the neuromuscular junction causes long-lasting and potentially fatal flaccid paralysis—a major feature of botulism. However, an intramuscular injection of minute amounts of BoNTs, primarily type A (BoNT-A), has useful long-lasting muscle relaxation effects on spastic motor disorders. This characteristic of BoNT-A is widely used in neurology and cosmetics. Over the last few decades, it has been demonstrated that the functions of BoNT-A are not limited to muscle-relaxing or autonomic cholinergic effects but that it can act as an analgesic agent as well. More recently, it was revealed that this antinociceptive effect starts after entering the sensory nerve endings, where these agents are axonally transported to the central nervous system, suggesting that at least part of their analgesic effect might be of central origin. Because of its antinociceptive effect, BoNT-A is currently approved for treatment of chronic migraine; nonetheless, case reports and preclinical and clinical experiments indicating its benefit in numerous potential painful conditions have increased. In the field of dentistry, the US Food and Drug Administration approved BoNT-A for the treatment of sialorrhea only. Legal status of the use of BoNT-A in other countries is less known. However, there are controlled clinical trials suggesting its efficacy in other conditions, such as bruxism, temporomandibular disorders, and trigeminal neuropathic pain. Thereby, using criteria of the American Academy of Neurology, we critically reviewed the uses of BoNTs in oral medicine and found it effective for trigeminal neuralgia (category A) and probably effective in temporomandibular disorders and bruxism.

show abstract

Section: Preclinical Researchmentioning

confidence: 75%

Botulinum Toxin Type A in Dental Medicine

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Infecções Relacionadas à Assistência à Saúde (IRAS) são adquiridas durante procedimentos no âmbito hospitalar, apresentando altos índices de morbimortalidade e alta incidência nos serviços de saúde do Brasil (ANVISA, 2017a). Constituem um grave problema de saúde pública pelos impactos sociais e financeiros que causam devido ao uso inadequado e indiscriminado de antimicrobianos com consequente seleção de bactérias resistentes (OLIVEIRA et al, 2016).…”

Section: Introductionunclassified

Anais Do I Congresso Luso-Brasileiro De Atenção Integral À Saúde (On-Line) - Resumos Expandidos

2021

View full text Add to dashboard Cite

Em tempos pandêmicos, o mundo enfrenta um desafio nunca antes visto para os sistemas de saúde de todas as nações. Deste modo, a troca de informações entre todos os afetados serve como atalho para atingir o objetivo de retornarmos à vida cotidiana normal.O I Congresso Luso-Brasileiro de Atenção Integral à Saúde (on-line) -I COLUBRAIS foi um evento internacional, que objetivou o intercâmbio de conhecimento entre os profissionais de Portugal e Brasil, mostrando o que há de melhor nos dois países, bem como oportunizou a divulgação científica dos participantes.O I COLUBRAIS ocorreu nos dias 11 e 12 de dezembro de 2021, com mais de 900 participantes.Contou com palestras e submissão de resumos nas modalidades simples e expandidos, foi dado aos participantes certificado de participação de 20 horas. Os três melhores trabalhos nas modalidades simples e expandidos receberão certificados de menção honrosa. Conheçam os títulos vencedores por ordem de submissão.

show abstract

“…The percutaneous injection of botulinum toxin (BoNT) into the salivary glands has been shown to be safe and effective in treating sialorrhea caused by neurological disorders in several randomised controlled trials (RCTs) [16][17][18][19][20][21][22][23][24]. The rationale for the use of BoNT is the selective inhibition of presynaptic acetylcholine release from the parasympathetic nerve terminals supplying eccrine salivary glands, thereby reducing saliva production [25,26]. Clinical studies vary in the type and dose of BoNT used (type A or B), glands injected (parotid, submandibular or both), population and cause of sialorrhea, inclusion of placebo-control arm, and anatomic or ultrasound-guided injections.…”

Section: Introductionmentioning

confidence: 99%

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions

Makino¹,

Mahant

Tilden³

et al. 2020

Neurol Ther

View full text Add to dashboard Cite

Introduction: Sialorrhea is a common and debilitating symptom associated with neurological conditions, which can result in considerable physical and psychosocial complications. In Australia, management options are limited and further impeded by the lack of approved treatments. Whilst there is emerging evidence for the efficacy and tolerability of botulinum toxin (BoNT) for the treatment of sialorrhea in patients with neurological conditions, the costeffectiveness of the treatment is yet to be established. Objectives: To evaluate the cost-effectiveness of incobotulinumtoxinA for the treatment of chronic troublesome sialorrhea caused by various neurological conditions from the Australian healthcare perspective. Methods: A Markov state transition model was developed to perform a cost-utility analysis comparing incobotulinumtoxinA with standard of care (SoC). The model consisted of a Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.11897370.

show abstract

Histological and immunohistochemical findings of the action of botulinum toxin in salivary gland: systematic review

Cited by 12 publications

References 44 publications

Botulinum Toxin Type A in Dental Medicine

Botulinum Toxin Type A in Dental Medicine

Anais Do I Congresso Luso-Brasileiro De Atenção Integral À Saúde (On-Line) - Resumos Expandidos

Cost-Effectiveness of IncobotulinumtoxinA in the Treatment of Sialorrhea in Patients with Various Neurological Conditions

Contact Info

Product

Resources

About